Each year cardiovascular disease (CVD) causes over 4 million deaths in Europe and 1.9 million deaths in the European Union (EU). Although the rates of death attributed to CVD have declined over the years, the burden of the disease remains high and on-going research into cardiovascular medicine remains vital. Through clinical and scientific research, we can study a variety of risk factors, treatments, and outcomes. How does nationality contribute to a person’s risk of suffering a major cardiac event? How can temperature management contribute to post-cardiac arrest care? Meet some of the people behind the trials and studies with the European Heart Journal.
The CANHEART Study
Thomas Lüscher, Professor and Chairman of Cardiology at the University Hospital Zurich, speaks with Jack V. Tu, Professor of Medicine at University of Toronto, and Leslie H. Curtis, Associate Professor in Medicine at Duke University, about the CANHEART Study at the Annual Scientific Sessions of the American Heart Association, Dallas, Texas. The CANHEART Study examined the 10-year incidence rates of major cardiovascular events in 697,690 immigrants to Ontario, Canada.
The TOPCAT Trial
Thomas Lüscher, Professor and Chairman of Cardiology at the University Hospital Zurich, speaks with Bertram Pitt, Professor of Medicine Emeritus at University of Michigan School of Medicine, and Marc Pfeffer, Dzau Professor at Harvard Medical School, about the TOPCAT Trial at the Annual Scientific Sessions of the American Heart Association, Dallas, Texas. The Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial examined the impact of spironolactone on primary outcomes, hospitalizations, and survivals.
The Targeted Temperature Management (TTM) Trial
Dr Benjamin Abella, University of Pennysylvania and discussant at the American Heart Association, speaks with Dr. Niklas Nielsen, of Lund University, Sweden, about the Targeted Temperature Management (TTM) Trial for post-arrest care. The TTM Trial compared two target temperatures intended to prevent fever (therapeutic hypothermia) for unconscious survivors of out-of-hospital cardiac arrest.